HC Wainwright Issues Pessimistic Forecast for CTXR Earnings

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – Stock analysts at HC Wainwright dropped their FY2024 EPS estimates for Citius Pharmaceuticals in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($0.26) per share for the year, down from their prior estimate of ($0.21). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Citius Pharmaceuticals’ current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.18) EPS.

Citius Pharmaceuticals Stock Down 39.1 %

NASDAQ:CTXR opened at $0.20 on Thursday. The company’s 50 day moving average price is $0.44 and its 200-day moving average price is $0.60. Citius Pharmaceuticals has a 52 week low of $0.19 and a 52 week high of $1.07. The stock has a market cap of $36.15 million, a price-to-earnings ratio of -1.34 and a beta of 1.66.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Point72 DIFC Ltd bought a new position in Citius Pharmaceuticals during the second quarter valued at approximately $29,000. XTX Topco Ltd bought a new position in Citius Pharmaceuticals in the third quarter worth approximately $47,000. Miller Investment Management LP raised its position in Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after acquiring an additional 49,640 shares during the period. BNP Paribas Financial Markets raised its position in Citius Pharmaceuticals by 88.5% in the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock worth $62,000 after acquiring an additional 32,686 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in Citius Pharmaceuticals in the second quarter worth approximately $69,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.